PALYNZIQ DIN 02526263
Status: Marketed
Holder: BIOMARIN INTERNATIONAL LIMITED
Health Canada record
| Active ingredient(s) | PEGVALIASE 20 MG |
|---|
| Dosage form | Solution |
|---|
| Route | Subcutaneous |
|---|
| Schedule | SCHEDULE D; PRESCRIPTION |
|---|
| Class | Human |
|---|
| ATC | A16AB19 PEGVALIASE |
|---|
| Original market date | 26-Aug-2022 |
|---|
| Current status date | 26-Aug-2022 |
|---|
| Source | Health Canada DPD |
|---|
Establishment licence of the holder
BioMarin International Limited — licence , not currently licensed, last inspection rating C (2024-02-16).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing PEGVALIASE
| DIN | Product | Company | Form | Strength | Status |
|---|
| 02526247 | PALYNZIQ | BIOMARIN INTERNATIONAL LIMITED | Solution | PEGVALIASE 2.5 MG | Marketed |
| 02526255 | PALYNZIQ | BIOMARIN INTERNATIONAL LIMITED | Solution | PEGVALIASE 10 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|
| 27856 | 2022-03-30 | New Drug Submission (NDS) | |
Request a quote for PALYNZIQ
How to read a Canadian DIN record